16 February 2024: Clinical Research
Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center
Tatsushi Mutoh 1ABCDEF* , Hiroaki Aono 1BDE , Wataru Seto 2BE , Takehiro Kimoto 2BE , Ryota Tochinai 3DE , Junta Moroi 1BE , Tatsuya Ishikawa 1DEDOI: 10.12659/MSM.943303
Med Sci Monit 2024; 30:e943303
Table 1 Univariate analysis of general clinical data for clazosentan therapy between completed and discontinued groups among 40 postoperative SAH patients.
| Treatment of clazosentan | P | ||
|---|---|---|---|
| Completed (n=31) | Discontinued (n=9) | ||
| Age (y) | 60.5 (12.6) | 67.7 (14.0) | 0.39 |
| Age of 75 years and older | 3 (9) | 4 (44) | |
| Women | 24 (77) | 7 (78) | 0.67 |
| Body weight (kg) | 60.9 (13.1) | 58.8 (11.5) | 0.13 |
| WFNS grade | 2.2 (1.5) | 2.2 (1.7) | 0.58 |
| Location of aneurysms | 0.46 | ||
| Anterior circulation | 28 (90) | 9 (100) | |
| Posterior circulation | 3 (10) | 0 (0) | |
| Ttreatment | |||
| Surgical clipping | 21 (68) | 7 (78) | 0.44 |
| Endovascular coiling | 10 (32) | 2 (22) | |
| Duration of drug therapy | 13.1 (1.6) | 4.7 (2.4) | |
| eGFR (mL/min/1.73 m) | |||
| On admission | 80.0 (25.5) | 85,5 (24.1) | 10.36 |
| At peak | 80.4 (33.9) | 107.2 (32.3) | 0.06 |
| BNP (pg/mL) | |||
| On admission | 36.6 (22.7) | 73.5 (74.2) | 0.72 |
| At peak | 119.6 (98.2) | 77.0 (58.7) | 0.06 |
| Peak urine volume | |||
| 24-h volume (mL/d) | 2,135 (730) | 1,285 (354) | |
| Volume per hour (mL/kg/h) | 1.35 (0.83) | 0.95 (0.31) | |
| Day-to-day variance (mL/kg/h) | −0.52 (0.54) | −0.96 (0.49) | |
| Daily fluid balance (mL/d) | 1,987 (781) | 2,068 (878) | 0.81 |
| Weight gain (kg) | 2.5 (1.9) | 3.2 (1.8) | 0.12 |
| Vasospasm | 8 (26) | 4 (44) | 0.25 |
| DCI | 4 (12) | 2 (22) | 0.41 |
| Data are shown as mean±SD (range) or number (percentage). Statistically significant results at | |||